Syngene International Ltd
As of 20 Nov 2026, Syngene International is in Stage 1, the basing phase, now in its first week (since 17 Nov 2026). It closed at ₹452, 31.6% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More about the company
Pro read
ProSYNGENE is basing for in its first week, above its 50-day average; it has not started an uptrend yet.
Its relative strength is 23 of 99, below the middle among NSE stocks over the past year. Labs & Life Sciences Services ranks 70 of 106 industries by the strength of its stocks.
Is SYNGENE early, or has it already run? Pro answers that for every NSE stock, after every close.
SYNGENE among Labs & Life Sciences Services4th of 6 by relative strength
All 6 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | DIVISLAB | Stage 2 · wk 26 | 93 | +21.7% |
| 2 | AARTIPHARM | Stage 2 · wk 13 | 84 | +17.5% |
| 3 | VIMTALABS | Stage 3 · wk 5 | 30 | −4.3% |
| 4 | SYNGENE | Stage 1 · wk 1 | 23 | +20.0% |
| 5 | BROOKS | Stage 1 · wk 3 | 16 | +10.6% |
| 6 | DCAL | Stage 4 · wk 14 | 5 | −18.7% |
Mutual fund holdings
Held by 80 mutual funds in portfolios to October 2026: 49 active funds and 31 index funds and ETFs.
In October, among active funds: 11 increased, 2 opened a new position, 2 reduced and 1 exited.
All 80 funds, the 1 that exited, and what each did in October
Mutual funds holding SYNGENE: the ten largest and the month’s moves →
Syngene International: quick answers
What stage is Syngene International in?
As of 20 Nov 2026, Syngene International (SYNGENE) is in Stage 1, the basing phase. It entered Stage 1 on 17 Nov 2026 and is in its first week there. What the four stages mean
Is Syngene International in an uptrend?
Not yet. Syngene International is in Stage 1, a base that can come before an uptrend. It trades 7.8% above its 200-day average, which is falling.
How far is Syngene International from its 52-week high?
Syngene International closed at ₹452 on 20 Nov 2026, 31.6% below its 52-week high of ₹660. Its 52-week low is ₹346.
How has Syngene International performed over the past year?
As of 20 Nov 2026, Syngene International is down 31.8% over the past year and down 30.6% so far in 2026.
Which sector and industry is Syngene International in?
Syngene International is in the Labs & Life Sciences Services industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care
About this companyHealth Care· Labs & Life Sciences Services
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.